Last $11.19 USD
Change Today +0.28 / 2.57%
Volume 1.1M
MACK On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

merrimack pharmaceuticals in (MACK) Snapshot

Open
$11.00
Previous Close
$10.91
Day High
$11.38
Day Low
$11.00
52 Week High
12/26/14 - $11.38
52 Week Low
04/28/14 - $4.13
Market Cap
1.2B
Average Volume 10 Days
2.2M
EPS TTM
$-1.04
Shares Outstanding
105.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MERRIMACK PHARMACEUTICALS IN (MACK)

merrimack pharmaceuticals in (MACK) Related Bloomberg News

View More Bloomberg News

merrimack pharmaceuticals in (MACK) Related Businessweek News

No Related Businessweek News Found

merrimack pharmaceuticals in (MACK) Details

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development include MM-398, a stable nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is in multiple ongoing Phase I, Phase II, Phase III clinical trials for the treatment of various cancers; MM-121, a human monoclonal antibody that targets the ErbB3 cell surface receptor, which is in multiple ongoing Phase I and Phase II clinical trials to inhibit cancer growth directly; and MM-111, a bispecific antibody that is in multiple ongoing Phase I and Phase II clinical trials to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor. The company’s product candidates also include MM-302, an antibody drug conjugated liposomal doxorubicin that is in Phase I clinical trials for advanced ErbB2 positive breast cancer; MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, which is in Phase I clinical trials for refractory solid tumors; and MM-141, a human tetravalent bispecific antibody that is in Phase I clinical trials to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth factor 1 receptor(IGF-1R) and ErbB3. Its therapeutic oncology product candidates are used in the treatment of various cancers, including pancreatic, colorectal, gastric, glioma, ovarian, breast, lung, and other gynecological cancers. The company has collaboration and license agreements with Actavis, Sanofi, PharmaEngine, Inc., Dyax Corp., Adimab LLC, University of California, U.S. Public Health Service, and Selexis SA. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

254 Employees
Last Reported Date: 03/4/14
Founded in 1993

merrimack pharmaceuticals in (MACK) Top Compensated Officers

Chief Executive Officer, President, Executive...
Total Annual Compensation: $512.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $284.6K
Senior Vice President of Corporate Operations
Total Annual Compensation: $343.3K
Senior Vice President of Business Development...
Total Annual Compensation: $305.7K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $364.6K
Compensation as of Fiscal Year 2013.

merrimack pharmaceuticals in (MACK) Key Developments

Merrimack Pharmaceuticals, Inc. Announces Board Changes

Merrimack Pharmaceuticals, Inc. announced the election of Russell T. Ray to its board of directors, effective January 1, 2015. Ray is a leading investment banker and venture capital investor in the life sciences sector, and has served as a director and advisor for many prominent companies in the healthcare sector during his 30 years of experience. Ray began his career in investment banking as a member of the High Tech Emerging Growth Group at Merrill Lynch. After his time at Merrill Lynch, Ray spent twelve years at Deutsche Bank and its predecessor entities, BT Alex. Brown and Alex. Brown & Sons, as a managing director and global head of Healthcare Investment Banking. Ray then joined Credit Suisse First Boston and served as a Managing Director and Global Co-Head of Healthcare Investment Banking where he focused on providing strategic and financial advice to life sciences, healthcare services and medical device companies. Merrimack also announced the retirement of Sarah Nash from board, effective December 31, 2014.

Merrimack Pharmaceuticals, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 03:20 PM

Merrimack Pharmaceuticals, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 03:20 PM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Edward J. Stewart, Senior Vice President of Business Development and President of Merrimack Healthcare Solutions.

Merrimack Pharmaceuticals, Inc. Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer

Merrimack Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted MM-398 (nanoliposomal irinotecan injection), also known as "nal-IRI," Fast Track designation for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. Fast Track is designed by the FDA to facilitate and expedite the development and review of drugs that treat serious conditions and fill an unmet medical need. Pancreatic cancer is the fourth cause of cancer-related deaths in the United States and is projected to be the second high cause of death from cancer in the United States by 2020. It is a rare and deadly disease that is difficult to diagnose and has limited treatment options available. Merrimack is currently preparing a New Drug Application (NDA) for MM-398 in the United States for the treatment of patients with metastatic pancreatic cancer previously treated with a gemcitabine-based therapy. Fast Track designation allows sections of the NDA to be submitted to the FDA as they are completed. Based upon this designation, Merrimack expects to initiate the NDA submission in 2014 with the goal of completing the NDA submission late in the first quarter or early in the second quarter of 2015. The US FDA and European Medicines Agency have granted MM-398 orphan drug designation in metastatic pancreatic cancer. Merrimack and Baxter International's biopharmaceutical business entered into an exclusive licensing agreement to develop and commercialize MM-398 outside of the United States. Baxter expects to submit for regulatory approvals outside of the United States beginning in 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MACK:US $11.19 USD +0.28

MACK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MACK.
View Industry Companies
 

Industry Analysis

MACK

Industry Average

Valuation MACK Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERRIMACK PHARMACEUTICALS IN, please visit www.merrimackpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.